Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic testing specialist Illumina (NASDAQ: ILMN ) popped 12% today after the company's quarterly results and outlook topped Wall Street expectations.
So what: The stock has soared over the past year on better-than-expected growth, and today's second-quarter results -- profit spiked 53% on a revenue jump of 23% -- coupled with upbeat guidance for the full year only reinforce that trend. Additionally, management said that it saw a significant increase in product and service revenue all while booking less charges, giving analysts plenty of good vibes over its earnings quality going forward, as well.
Now what: Management now sees full-year adjusted EPS of $1.68-$1.72 on a revenue increase of 20%, well above its prior view of $1.55-$1.62 in adjusted EPS and a 15% bump on the top line.
"Our business demonstrated strong trends globally and our 2013 strategic initiatives for robust long-term growth are progressing as planned," said President and CEO Jay Flatley. "As a result we are raising our expectations for 2013 financial performance."
Of course, with the stock now up more than 100% over its 52-week lows and trading at a forward P/E of around 40, much of those expectations might already be baked into the valuation.
It's no secret that biotech stocks like Illumina have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.